Which has better earnings and valuation, ZBIO or VSTM?

Verastem has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zenas BioPharma $10M 193.81 -$377.74M -$8.47 N/A Verastem $30.91M 16.35 -$209.47M -$2.70 N/A

Is ZBIO or VSTM more profitable?

Zenas BioPharma has a net margin of 0.00% compared to Verastem's net margin of -391.17%. Zenas BioPharma's return on equity of -99.99% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -99.99% -58.06% Verastem -391.17% -486.40% -91.56%

Does the media refer more to ZBIO or VSTM?

In the previous week, Zenas BioPharma and Zenas BioPharma both had 4 articles in the media. Zenas BioPharma's average media sentiment score of 0.68 beat Verastem's score of 0.32 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, VSTM or INVA?

Innoviva has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 16.35 -$209.47M -$2.70 N/A Innoviva $411.33M 3.82 $271.17M $6.01 3.54

Is VSTM or INVA more profitable?

Innoviva has a net margin of 119.89% compared to Verastem's net margin of -391.17%. Innoviva's return on equity of 33.33% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% Innoviva 119.89% 33.33% 22.67%

Which has better earnings and valuation, VSTM or NVAX?

Novavax has higher revenue and earnings than Verastem. Novavax is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 16.35 -$209.47M -$2.70 N/A Novavax $1.12B 1.15 $440.30M -$0.58 N/A

Is VSTM or NVAX more profitable?

Novavax has a net margin of -14.73% compared to Verastem's net margin of -391.17%. Novavax's return on equity of -14.82% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% Novavax -14.73% -14.82% 1.23%

Does the media favor VSTM or NVAX?

In the previous week, Novavax had 2 more articles in the media than Verastem. MarketBeat recorded 6 mentions for Novavax and 4 mentions for Verastem. Novavax's average media sentiment score of 0.41 beat Verastem's score of 0.32 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novavax 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, VSTM or MNKD?

MannKind has higher revenue and earnings than Verastem. MannKind is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 16.35 -$209.47M -$2.70 N/A MannKind $348.97M 3.52 $5.86M -$0.07 N/A

Is VSTM or MNKD more profitable?

MannKind has a net margin of -6.63% compared to Verastem's net margin of -391.17%. MannKind's return on equity of -11.21% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% MannKind -6.63% -11.21% -3.92%

Does the media prefer VSTM or MNKD?

In the previous week, MannKind had 3 more articles in the media than Verastem. MarketBeat recorded 7 mentions for MannKind and 4 mentions for Verastem. MannKind's average media sentiment score of 0.67 beat Verastem's score of 0.32 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, VSTM or OPK?

Verastem has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 16.35 -$209.47M -$2.70 N/A OPKO Health $606.90M 1.49 -$225.68M -$0.27 N/A

Is VSTM or OPK more profitable?

OPKO Health has a net margin of -36.63% compared to Verastem's net margin of -391.17%. OPKO Health's return on equity of -16.78% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% OPKO Health -36.63% -16.78% -10.98%

Does the media prefer VSTM or OPK?

In the previous week, Verastem had 3 more articles in the media than OPKO Health. MarketBeat recorded 4 mentions for Verastem and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.44 beat Verastem's score of 0.32 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Verastem (VSTM) Competitors

$5.75 -0.28 (-4.64%)

Closing price 04:00 PM Eastern

Extended Trading

$5.78 +0.03 (+0.43%)

As of 07:59 PM Eastern

Compare

VSTM vs. ZBIO, INVA, NVAX, MNKD, and OPK

Should you buy Verastem stock or one of its competitors? MarketBeat compares Verastem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verastem include Zenas BioPharma (ZBIO), Innoviva (INVA), Novavax (NVAX), MannKind (MNKD), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry.

How does Verastem compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Zenas BioPharma currently has a consensus target price of $44.29, suggesting a potential upside of 44.25%. Verastem has a consensus target price of $14.40, suggesting a potential upside of 150.43%. Given Verastem's stronger consensus rating and higher probable upside, analysts clearly believe Verastem is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Zenas BioPharma has a net margin of 0.00% compared to Verastem's net margin of -391.17%. Zenas BioPharma's return on equity of -99.99% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Verastem	-391.17%	-486.40%	-91.56%

88.4% of Verastem shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 1.9% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zenas BioPharma has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market. Comparatively, Verastem has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Verastem has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	193.81	-$377.74M	-$8.47	N/A
Verastem	$30.91M	16.35	-$209.47M	-$2.70	N/A

In the previous week, Zenas BioPharma and Zenas BioPharma both had 4 articles in the media. Zenas BioPharma's average media sentiment score of 0.68 beat Verastem's score of 0.32 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Verastem beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Verastem compare to Innoviva?

Verastem (NASDAQ:VSTM) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Innoviva has a net margin of 119.89% compared to Verastem's net margin of -391.17%. Innoviva's return on equity of 33.33% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Innoviva	119.89%	33.33%	22.67%

Verastem presently has a consensus price target of $14.40, indicating a potential upside of 150.43%. Innoviva has a consensus price target of $36.20, indicating a potential upside of 70.11%. Given Verastem's stronger consensus rating and higher possible upside, analysts clearly believe Verastem is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

88.4% of Verastem shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Innoviva has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	16.35	-$209.47M	-$2.70	N/A
Innoviva	$411.33M	3.82	$271.17M	$6.01	3.54

In the previous week, Verastem had 4 more articles in the media than Innoviva. MarketBeat recorded 4 mentions for Verastem and 0 mentions for Innoviva. Verastem's average media sentiment score of 0.32 beat Innoviva's score of 0.00 indicating that Verastem is being referred to more favorably in the media.

Company	Overall Sentiment
Verastem	Neutral
Innoviva	Neutral

Verastem has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Summary

Innoviva beats Verastem on 10 of the 17 factors compared between the two stocks.

How does Verastem compare to Novavax?

Verastem (NASDAQ:VSTM) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Verastem has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Novavax has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

In the previous week, Novavax had 2 more articles in the media than Verastem. MarketBeat recorded 6 mentions for Novavax and 4 mentions for Verastem. Novavax's average media sentiment score of 0.41 beat Verastem's score of 0.32 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novavax	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verastem currently has a consensus price target of $14.40, suggesting a potential upside of 150.43%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 64.97%. Given Verastem's stronger consensus rating and higher probable upside, analysts plainly believe Verastem is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

88.4% of Verastem shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.9% of Verastem shares are held by insiders. Comparatively, 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Novavax has higher revenue and earnings than Verastem. Novavax is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	16.35	-$209.47M	-$2.70	N/A
Novavax	$1.12B	1.15	$440.30M	-$0.58	N/A

Novavax has a net margin of -14.73% compared to Verastem's net margin of -391.17%. Novavax's return on equity of -14.82% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Novavax	-14.73%	-14.82%	1.23%

Summary

Novavax beats Verastem on 9 of the 17 factors compared between the two stocks.

How does Verastem compare to MannKind?

Verastem (NASDAQ:VSTM) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

MannKind has higher revenue and earnings than Verastem. MannKind is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	16.35	-$209.47M	-$2.70	N/A
MannKind	$348.97M	3.52	$5.86M	-$0.07	N/A

Verastem has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, MannKind has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Verastem presently has a consensus price target of $14.40, suggesting a potential upside of 150.43%. MannKind has a consensus price target of $8.97, suggesting a potential upside of 125.35%. Given Verastem's stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

MannKind has a net margin of -6.63% compared to Verastem's net margin of -391.17%. MannKind's return on equity of -11.21% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
MannKind	-6.63%	-11.21%	-3.92%

88.4% of Verastem shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 1.9% of Verastem shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, MannKind had 3 more articles in the media than Verastem. MarketBeat recorded 7 mentions for MannKind and 4 mentions for Verastem. MannKind's average media sentiment score of 0.67 beat Verastem's score of 0.32 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MannKind beats Verastem on 10 of the 16 factors compared between the two stocks.

How does Verastem compare to OPKO Health?

Verastem (NASDAQ:VSTM) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

88.4% of Verastem shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 44.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OPKO Health has a net margin of -36.63% compared to Verastem's net margin of -391.17%. OPKO Health's return on equity of -16.78% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
OPKO Health	-36.63%	-16.78%	-10.98%

Verastem has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	16.35	-$209.47M	-$2.70	N/A
OPKO Health	$606.90M	1.49	-$225.68M	-$0.27	N/A

Verastem presently has a consensus target price of $14.40, indicating a potential upside of 150.43%. OPKO Health has a consensus target price of $1.55, indicating a potential upside of 29.17%. Given Verastem's stronger consensus rating and higher possible upside, equities analysts clearly believe Verastem is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Verastem has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

In the previous week, Verastem had 3 more articles in the media than OPKO Health. MarketBeat recorded 4 mentions for Verastem and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.44 beat Verastem's score of 0.32 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OPKO Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Verastem beats OPKO Health on 9 of the 17 factors compared between the two stocks.

Get Verastem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VSTM vs. The Competition

Export

Metric	Verastem	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$529.88M	$3.69B	$6.90B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-2.13	20.49	27.10	23.94
Price / Sales	16.35	300.39	517.51	91.92
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	7.77	7.92	10.66	6.14
Net Income	-$209.47M	$23.81M	$3.60B	$331.74M
7 Day Performance	7.08%	-1.27%	-1.51%	-1.72%
1 Month Performance	39.56%	2.56%	1.11%	-1.44%
1 Year Performance	11.43%	42.49%	23.77%	16.97%

Verastem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VSTM Verastem	3.1607 of 5 stars	$5.75 -4.6%	$14.40 +150.4%	+16.9%	$529.88M	$30.91M	N/A	50
ZBIO Zenas BioPharma	3.6887 of 5 stars	$27.88 -3.0%	$44.29 +58.8%	+115.1%	$1.81B	$10M	N/A	N/A
INVA Innoviva	2.9278 of 5 stars	$22.21 -0.1%	$36.20 +63.0%	+10.9%	$1.64B	$411.33M	3.70	100
NVAX Novavax	2.1273 of 5 stars	$8.91 -4.5%	$13.00 +45.9%	+17.3%	$1.53B	$1.12B	N/A	1,990
MNKD MannKind	3.6031 of 5 stars	$4.04 -1.2%	$8.97 +122.0%	+7.2%	$1.26B	$348.97M	N/A	400	News Coverage Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VSTM) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verastem (VSTM) Competitors

VSTM vs. ZBIO, INVA, NVAX, MNKD, and OPK

How does Verastem compare to Zenas BioPharma?

Summary

How does Verastem compare to Innoviva?

Summary

How does Verastem compare to Novavax?

Summary

How does Verastem compare to MannKind?

Summary

How does Verastem compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verastem (VSTM) Competitors

VSTM vs. ZBIO, INVA, NVAX, MNKD, and OPK

How does Verastem compare to Zenas BioPharma?

Do analysts prefer ZBIO or VSTM?

Is ZBIO or VSTM more profitable?

Do institutionals and insiders hold more shares of ZBIO or VSTM?

Which has more volatility and risk, ZBIO or VSTM?

Which has better earnings and valuation, ZBIO or VSTM?

Does the media refer more to ZBIO or VSTM?

Summary

How does Verastem compare to Innoviva?

Is VSTM or INVA more profitable?

Do analysts prefer VSTM or INVA?

Do insiders and institutionals hold more shares of VSTM or INVA?

Which has stronger earnings & valuation, VSTM or INVA?

Does the media favor VSTM or INVA?

Which has more risk & volatility, VSTM or INVA?

Summary

How does Verastem compare to Novavax?

Which has more volatility & risk, VSTM or NVAX?

Does the media favor VSTM or NVAX?

Do analysts rate VSTM or NVAX?

Do institutionals & insiders have more ownership in VSTM or NVAX?

Which has better earnings and valuation, VSTM or NVAX?

Is VSTM or NVAX more profitable?

Summary

How does Verastem compare to MannKind?

Which has better valuation & earnings, VSTM or MNKD?

Which has more volatility & risk, VSTM or MNKD?

Do analysts recommend VSTM or MNKD?

Is VSTM or MNKD more profitable?

Do insiders & institutionals have more ownership in VSTM or MNKD?

Does the media prefer VSTM or MNKD?

Summary

How does Verastem compare to OPKO Health?

Do institutionals & insiders hold more shares of VSTM or OPK?

Is VSTM or OPK more profitable?

Which has higher valuation & earnings, VSTM or OPK?

Do analysts recommend VSTM or OPK?

Which has more volatility and risk, VSTM or OPK?

Does the media prefer VSTM or OPK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools